A Randomized Double-Blinded Study of Single-Dose Methylprednisolone to Prevent Kidney Injury in Adults Undergoing Elective Cardiac Surgery with Cardiopulmonary Bypass

What this Trial Is About

Researchers are investigating whether giving a single dose of methylprednisolone during cardiac surgery can reduce the risk of acute kidney injury after the operation. The study focuses on patients undergoing elective heart surgeries that require cardiopulmonary bypass. This research aims to understand if methylprednisolone can protect kidney function in this setting while monitoring other health outcomes. Participants will be randomly assigned to one of two groups one group will receive a single intravenous dose of methylprednisolone 2 mgkg after anesthesia is started and before cardiopulmonary bypass begins, while the other group will receive a placebo of normal saline at the same time. This is a double-blinded study, so neither the patients nor the researchers will know which treatment is given during the trial. During the study, participants will be closely monitored for seven days after surgery to assess the occurrence of acute kidney injury using specific criteria. Researchers will also track secondary outcomes like high blood sugar, length of ICU and hospital stays, wound infections, peptic ulcers, and sepsis. The total hospital stay is monitored up to 14 days post-surgery. Safety and recovery will be carefully evaluated throughout the trial period.

Prophylactic Methylprednisolone for Renal Protection in Cardiac Surgeries With Cardiopulmonary Bypass